- Home
- SERV vs CRVS Comparison
SERV vs CRVS Comparison
Compare SERV & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SERV | CRVS |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 724.7M | 634.0M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | SERV | CRVS |
|---|---|---|
| Price | $11.21 | $8.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $18.33 | $13.75 |
| AVG Volume (30 Days) | ★ 7.1M | 1.1M |
| Earning Date | 11-12-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,944,483.00 | N/A |
| Revenue This Year | $44.11 | N/A |
| Revenue Next Year | $925.57 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 15.76 | N/A |
| 52 Week Low | $4.66 | $2.54 |
| 52 Week High | $24.35 | $9.60 |
Technical Indicators
Market Signals| Indicator | SERV | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 47.81 | 50.42 |
| Support Level | $11.50 | $8.31 |
| Resistance Level | $13.70 | $9.60 |
| Average True Range (ATR) | 1.00 | 0.54 |
| MACD | 0.21 | -0.09 |
| Stochastic Oscillator | 41.04 | 23.25 |
Price Performance
Historical ComparisonAbout SERV Serve Robotics Inc.
Serve Robotics Inc is developing next-generation robots for last-mile delivery services. It design, develop and operate low-emissions robots on AI-powered robotics mobility platform, that serve people in public spaces, starting with food delivery. Its first product is a zero-emission robot that serves people in public areas, Starting with food delivery. It has developed an AI-robotics mobility platform, with last-mile delivery in cities as its first application.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).